Protective effect of PACAP against ultraviolet B radiation-induced human corneal endothelial cell injury.

Apoptosis / drug effects Cell Survival / drug effects Cells, Cultured Endothelial Cells / cytology Humans Pituitary Adenylate Cyclase-Activating Polypeptide / metabolism Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide / metabolism
Endothelial barrier Human corneal endothelial cells Pituitary adenylate cyclase activating polypeptide Ultraviolet insult

Journal

Neuropeptides
ISSN: 1532-2785
Titre abrégé: Neuropeptides
Pays: Netherlands
ID NLM: 8103156

Informations de publication

Date de publication:
Feb 2020
Historique:
received: 27 05 2019
revised: 10 10 2019
accepted: 10 10 2019
pubmed: 4 12 2019
medline: 24 11 2020
entrez: 4 12 2019
Statut: ppublish

Résumé

The human cornea, a sophisticated example of natural engineering, is composed in the innermost layer by endothelial cells maintaining stromal hydration and clarity. Different types of insults, including ultraviolet (UV) radiations, can lead to corneal opacity due to their degenerative and limited proliferative capability. In our previous studies, we have shown the protective effects of pituitary adenylate cyclase activating polypeptide (PACAP) in human corneal endothelial cells (HCECs), after growth factors deprivation. The aim of the present work has been to investigate the effect of this peptide on UV-B-induced HCECs injury. The results have shown that UV-B irradiations induced apoptotic cells death and consequently alteration in human corneal endothelial barrier. We found that PACAP treatment significantly increased viability, trans-endothelial electrical resistance and tight junctions expression of HCECs exposed to UV-B insult. In conclusion, data have suggested that this peptide could have protective effect to preserve the physiological state of human corneal endothelium exposed to UV-B damage.

Identifiants

DOI: 10.1016/j.npep.2019.101978 PMID: 31791645
pubmed: 31791645
pii: S0143-4179(19)30083-6
doi: 10.1016/j.npep.2019.101978
pii:
doi:

Substances chimiques

Pituitary Adenylate Cyclase-Activating Polypeptide 0
Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

101978

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Grazia Maugeri (G)

Department of Biomedical and Biotechnological Sciences, Section of Human Anatomy and Histology, University of Catania, Catania, Italy.

Agata Grazia D'Amico (AG)

Department of Human Science and Promotion of Quality of Life, San Raffaele Open University of Rome, Rome, Italy.

Alessia Amenta (A)

Department of Biomedical and Biotechnological Sciences, Section of Human Anatomy and Histology, University of Catania, Catania, Italy.

Salvatore Saccone (S)

Department of Biological, Geological, and Environmental Sciences, Section of Animal Biology, University of Catania, Catania, Italy.

Concetta Federico (C)

Department of Biological, Geological, and Environmental Sciences, Section of Animal Biology, University of Catania, Catania, Italy.

Michele Reibaldi (M)

Department of Ophthalmology, Eye Clinic, University of Catania, Catania, Italy.

Andrea Russo (A)

Department of Ophthalmology, Eye Clinic, University of Catania, Catania, Italy.

Vincenza Bonfiglio (V)

Department of Ophthalmology, Eye Clinic, University of Catania, Catania, Italy.

Teresio Avitabile (T)

Department of Ophthalmology, Eye Clinic, University of Catania, Catania, Italy.

Antonio Longo (A)

Department of Ophthalmology, Eye Clinic, University of Catania, Catania, Italy.

Velia D'Agata (V)

Department of Biomedical and Biotechnological Sciences, Section of Human Anatomy and Histology, University of Catania, Catania, Italy. Electronic address: vdagata@unict.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Phénomènes physiologiques cellulaires › Mort cellulaire › Mort cellulaire régulée › Apoptose › Protective effect of PACAP against ultraviolet...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Survie cellulaire › Protective effect of PACAP against ultraviolet...
questionsmedicales.fr › Cellules › Cellules cultivées › Protective effect of PACAP against ultraviolet...
questionsmedicales.fr › Cellules › Cellules épithéliales › Cellules endothéliales › Protective effect of PACAP against ultraviolet...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Protective effect of PACAP against ultraviolet...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Facteurs de croissance nerveuse › Polypeptide activateur de l'adénylcyclase hypophysaire › Protective effect of PACAP against ultraviolet...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs couplés aux protéines G › Récepteurs au polypeptide activateur de l'adénylcyclase hypophysaire › Protective effect of PACAP against ultraviolet...